Weill Cornell Medicine researchers received a $1 million PCF Challenge Award to develop an AI model for early detection of treatment-resistant prostate cancer subtypes.
Key Details
- 1Dr. Ekta Khurana leads the project, collaborating with Memorial Sloan Kettering Cancer Center.
- 2The team received a $1 million, two-year Prostate Cancer Foundation Challenge Award.
- 3Research focuses on AI models trained on pathology slides, gene activity, and treatment outcomes.
- 4Project aims to identify patients with tumors likely to develop resistance early so they can be matched to appropriate trials.
- 5Validation of the developed AI model in clinical trials is planned for a follow-on project.
Why It Matters
Developing AI tools to distinguish treatment-resistant tumor subtypes could significantly improve personalized care and trial selection for prostate cancer, addressing a pressing clinical need. Integration of pathology, genomics, and AI in this way is at the forefront of imaging-based precision medicine.
Source
EurekAlert
Related News
•EurekAlert
AI-Powered OCT Enables Rapid 'Optical Biopsy' for Early Endometrial Cancer Detection
A team at Washington University has developed a catheter-based 3D OCT system with AI to quickly and noninvasively detect early endometrial cancers.
•EurekAlert
AI Clinical Reasoning in Diagnostics and Digital Fatigue in Healthcare
Recent JMIR features explore large language models in clinical diagnostics and digital fatigue among healthcare professionals.
•EurekAlert
KAIST, MIT, Microsoft Develop Efficient AI Image Upsampling for Robotics
KAIST, MIT, and Microsoft have created 'Upsample Anything,' a training-free AI method to restore high-resolution visual data from compressed images with up to 16x improved GPU memory efficiency.